Prognostic value of enhancement rate by enhanced ultrasound in hepatitis B virus-positive hepatocellular carcinoma undergoing radiofrequency ablation.

AIM: To assess the prognostic significance of enhancement rate (ER) measured by contrast-enhanced ultrasonography (CEUS) in patients with hepatocellular carcinoma (HCC) undergoing radiofrequency ablation (RFA). MATERIALS AND METHODS: A total of 253 patients with single primary HCC undergoing preoperative CEUS and RFA were enrolled in this study. The ER were evaluated though pretreatment CEUS. After a mean follow-up of 36.8 ± 10.2 months, the correlation of ER measured by CEUS and survival after RFA was analyzed by univariate and multivariate analysis. The optimal cutoff ER value to predict survival was determined using receiver-operating characteristic analysis. RESULTS: Mean follow-up period for all 253 patients was 36.8 ± 10.2 months, 31.2% of patients had died at endpoint. The optimal cutoff ER value predicting survival was 2.2 dB/s. Univariate analysis demonstrated that patients with a high ER level had poorer OS (62.8 months vs 48.8 months, P = 0.02) and recurrence-free survival (RFS = 60.2 months vs 47.4 months, P = 0.03) than patients with a low ER level. ER measured by CEUS also been confirmed as independent risk factor for overall survival (hazard ratio [HR], 1.87; 95% confidence interval [95% CI], 1.21-7.25; P < 0.01) and RFS (HR, 1.67; 95% CI, 1.08-6.21; P < 0.01) in multivariate analysis enrolling gender, BMI, tumor size, antiviral therapy, HBV DNA, histological differentiation, Child-Pugh score and tumor node metastasis (TNM) stage. CONCLUSIONS: ER measured by CEUS was a significant predictive factor for survival after RFA for HCC.

Deficient zinc levels and myocardial infarction : association between deficient zinc levels and myocardial infarction: a meta-analysis.

The purpose of this study is to clarify the association between Zn levels and myocardial infarction (MI) using a meta-analysis approach. We searched articles in the PubMed, OVID, and ScienceDirect published as of November 2014. Thirteen eligible articles with 2886 subjects from 41 case-control studies were identified. Overall, pooled analysis indicated that subjects with MI had lower Zn levels than healthy controls (standardized mean difference (SMD) = -1.848, 95 % confidence interval (CI) = [-2.365, -1.331]). Further subgroup analysis found that subjects with MI had lower Zn levels than healthy controls in serum (SMD = -1.764, 95 % CI = [-2.417, -1.112]) and hair (SMD = -3.326, 95 % CI = [-4.616, -2.036]), but not in toenail (SMD = -0.396, 95 % CI = [-1.114, 0.322]). The subgroup analysis stratified by type of Zn measurement found a similar pattern in inductively coupled plasma-atomic absorption spectrometry (ICP-AAS) (SMD = -2.442, 95 % CI = [-3.092, -1.753]), but not in neutron activation analysis (NAA) (SMD = -0.449, 95 % CI = [-1.127, 0.230]). Lower Zn levels in MI patients were found both in male (SMD = -3.350, 95 % CI = [-4.531, -2.169]) and female (SMD = -2.681, 95 % CI = [-3.440, -1.922]). And the difference of Zn levels according to MI in Asia (SMD = -2.555, 95 % CI = [-3.267, -1.844]) was greater to that among the population in Europe (SMD = -0.745, 95 % CI = [-1.386, -0.104]), but no difference was found in Oceania (SMD = -0.255, 95 % CI = [-0.600, 0.089]). In conclusion, this meta-analysis indicates that there is a significant association between Zn deficiency and MI. We suggest that a community-based, long-term observation in a cohort design should be performed to obtain better understanding of causal relationships between Zn and MI, through measuring hair Zn at baseline to investigate whether the highest zinc category versus lowest was associated with MI risk.